Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obicetrapib - NewAmsterdam Pharma

Next Previous
Drug Profile

Obicetrapib - NewAmsterdam Pharma

Alternative Names: AMG 899; DEZ 001; obicetripib; TA-8995

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Amgen; Menarini; Mitsubishi Tanabe Pharma Corporation; NewAmsterdam Pharma
  • Class Antidementias; Antihyperlipidaemics; Heterocyclic compounds; Quinolines; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Dyslipidaemias; Hypercholesterolaemia
  • Phase III Hyperlipoproteinaemia type IIa; Metabolic syndrome; Type 2 diabetes mellitus
  • Phase II Alzheimer's disease

Most Recent Events

  • 09 Jan 2026 NewAmsterdam anticipates MAA approval in hypercholesterolemia and Dyslipidaemias in second half of 2026
  • 09 Jan 2026 NewAmsterdam plans a clinical trial for Alzheimer's disease (Early stage disease) in 2026
  • 31 Dec 2025 Phase-III clinical trials in Metabolic syndrome (PO) (NCT07219602)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top